BioLineRx's IFRS loss for 9M 2021 was $22.75 million, up 26.2% from $18.033 million in the prior year.
BioLineRx's IFRS loss for 9M 2021 was $22.75 million, up 26.2% from $18.033 million in the prior year.
Financial results
BioLineRx's IFRS loss for 9M 2021 was $22.75 million, up 26.2% from $18.033 million in the prior year. Source: 
ir.biolinerx.com
ir.biolinerx.com
English (US) 